Compare OpGen, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 8.24% and Operating profit at 15.29% over the last 5 years
3
Positive results in Dec 24
4
With ROE of -659.91%, it has a risky valuation with a 15.85 Price to Book Value
5
Market Beating performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
823.91%
0%
823.91%
6 Months
64785.5%
0%
64785.5%
1 Year
1940.0%
0%
1940.0%
2 Years
674.13%
0%
674.13%
3 Years
1293.44%
0%
1293.44%
4 Years
2752.35%
0%
2752.35%
5 Years
975.95%
0%
975.95%
OpGen, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.24%
EBIT Growth (5y)
15.29%
EBIT to Interest (avg)
-8.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.86%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
15.85
EV to EBIT
-7.71
EV to EBITDA
-8.23
EV to Capital Employed
27.07
EV to Sales
36.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-351.21%
ROE (Latest)
-659.91%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 2 Schemes (0.13%)
Foreign Institutions
Held by 5 Foreign Institutions (0.17%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ
Dec'24
Sep'24
Change(%)
Net Sales
5.00
0.00
Operating Profit (PBDIT) excl Other Income
4.50
-0.70
742.86%
Interest
0.00
0.00
Exceptional Items
0.00
10.30
-100.00%
Consolidate Net Profit
4.40
8.90
-50.56%
Operating Profit Margin (Excl OI)
895.30%
0.00%
89.53%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Sep 2024
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2024 is -50.56% vs 656.25% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
3.40
2.60
30.77%
Operating Profit (PBDIT) excl Other Income
-14.40
-20.60
30.10%
Interest
1.80
3.30
-45.45%
Exceptional Items
-2.00
-12.20
83.61%
Consolidate Net Profit
-32.70
-37.30
12.33%
Operating Profit Margin (Excl OI)
-4,589.50%
-8,521.80%
393.23%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 30.77% vs -39.53% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 12.33% vs -7.18% in Dec 2022
About OpGen, Inc. 
OpGen, Inc.
Miscellaneous
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Company Coordinates 
Company Details
708 Quince Orchard Rd Ste 205 , GAITHERSBURG MD : 20878-1793
Registrar Details






